Cite
P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma.
MLA
Ribas, A., et al. “P0116 Updated Clinical Efficacy of the Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients with Melanoma.” European Journal of Cancer, vol. 51, July 2015, p. e24. EBSCOhost, https://doi.org/10.1016/j.ejca.2015.06.072.
APA
Ribas, A., Wolchok, J. D., Robert, C., Kefford, R., Hamid, O., Daud, A., Hwu, W.-J., Weber, J. S., Joshua, A. M., Gangadhar, T. C., Patnaik, A., Hersey, P., Dronca, R., Zarour, H., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., & Kang, S. P. (2015). P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma. European Journal of Cancer, 51, e24. https://doi.org/10.1016/j.ejca.2015.06.072
Chicago
Ribas, A., J.D. Wolchok, C. Robert, R. Kefford, O. Hamid, A. Daud, W-J. Hwu, et al. 2015. “P0116 Updated Clinical Efficacy of the Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients with Melanoma.” European Journal of Cancer 51 (July): e24. doi:10.1016/j.ejca.2015.06.072.